Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07018453

A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

A Randomized, Open-label, Treat-to-target, Parallel-Controlled Phase II Clinical Study Investigating the Efficacy and Safety of SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
173 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the glycemic control and safety of SHR-3167 and Insulin Degludec in type 2 diabetic participants treated with basal insulin with or without oral antidiabetic drugs.

Conditions

Interventions

TypeNameDescription
DRUGSHR-3167SHR-3167 Injection.
DRUGInsulin DegludecInsulin Degludec Injection.

Timeline

Start date
2025-07-16
Primary completion
2026-02-01
Completion
2026-05-01
First posted
2025-06-12
Last updated
2025-11-18

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT07018453. Inclusion in this directory is not an endorsement.

A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without O (NCT07018453) · Clinical Trials Directory